Last reviewed · How we verify
177Lu-FAP-2286
177Lu-FAP-2286 is a radiolabeled antibody that targets folate receptor alpha (FRα) for the treatment of cancer.
177Lu-FAP-2286 is a radiolabeled antibody that targets folate receptor alpha (FRα) for the treatment of cancer. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | 177Lu-FAP-2286 |
|---|---|
| Sponsor | Peter MacCallum Cancer Centre, Australia |
| Drug class | Radiolabeled antibody |
| Target | Folate receptor alpha (FRα) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by selectively binding to FRα, which is overexpressed in certain types of cancer cells, allowing for targeted radiation therapy. This approach aims to minimize damage to healthy tissues while maximizing the therapeutic effect on cancer cells.
Approved indications
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (PHASE1, PHASE2)
- Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary (PHASE2)
- 177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 177Lu-FAP-2286 CI brief — competitive landscape report
- 177Lu-FAP-2286 updates RSS · CI watch RSS
- Peter MacCallum Cancer Centre, Australia portfolio CI